Разработка и регистрация лекарственных средств (Sep 2022)

Development of a Method and a Scheme for the Use of a Live Recombinant Vaccine "GamLPV". Safety and Tolerability of Double Intranasal Vaccination of Healthy Adult Volunteers

  • G. I. Karataev,
  • A. Yu. Medkova,
  • E. G. Semin,
  • L. N. Sinyashina,
  • R. A. Sioundioukova,
  • S. V. Kulikov,
  • N. A. Snegireva,
  • I. N. Chernishova,
  • M. V. Gavrilova,
  • K. K. Bushkova,
  • A. A. Lidzhieva,
  • L. V. Kolobukhina,
  • I. S. Kruzhkova,
  • L. N. Merkulova,
  • M. G. Rusanova,
  • M. V. Bazarova,
  • N. A. Antipyat,
  • S. V. Smetanina,
  • E. A. Smolyarchuk,
  • I. N. Dyakov

DOI
https://doi.org/10.33380/2305-2066-2022-11-3-202-208
Journal volume & issue
Vol. 11, no. 3
pp. 202 – 208

Abstract

Read online

Introduction. The increase in the incidence of whooping cough in children and adults of different age groups justifies the need for their revaccination and the development of new, acceptable for these purposes. This work is devoted to substantiating the design of a clinical trial and describing the results of a comparative study of the safety and tolerability of the drug "GamLPV" with two-fold intranasal administration to healthy adult volunteers using two methods. The choice of the scheme and method of administration of the drug is justified. The serological structure of the population of adults aged 18–40 years living in Moscow and the Moscow region is characterized.Aim. Determination of the safety and tolerability of the drug with a double intranasal administration of the vaccine by drip method and spraying through an actuator.Materials and methods. A randomized placebo-controlled trial included 50 healthy male and female volunteers aged 18 to 40 years who met the inclusion criteria. The volunteers were divided into 2 groups of 25 people: a drip method of administration and spraying through an "actuator". By both methods, the drug was administered twice with an interval of 60 days.Results and discussion. Serological analysis of the population of healthy volunteers at the prescreening stage justified the inclusion in the study of volunteers containing anti-pertussis antibodies in the blood (IgG ≤40 Ed/ml). A comparison of the results of preclinical studies on an experimental model of non-human monkeys and the first phase of a clinical study of GamLPV allowed us to propose two methods of double administration of the drug as a promising vaccination scheme for volunteers. A comparative randomized study shows the safety of using the proposed scheme for vaccination of adult volunteers.Conclusions. Both proposed methods of double administration can be used to plan a multicenter study to research the immunogenicity and protective activity of GamLPV.

Keywords